Navamedic on track to launch eight generics; sales rise 43%
Norwegian drugmaker Navamedic ASA (OSE: NAVA) says sales in the second quarter of 2011 were record high for the third consecutive quarter. The development of Navamedic's new generic drug business remains on track, and the company predicts profitability and significant sales growth in 2012.
Turnover for the quarter reached 18.2 million Norwegian kroner ($3.3 million), a rise of 43% of the like year-earlier period. All sales were generated by the Vitaflo business area, a distributor of patented drugs and health care products in the Nordic markets. For the first half of 2011 sales were up 36% to 35.0 million kroner.
10 generics filed for approval
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze